US cloud software company selling industry-specific applications for life sciences (pharma/biotech) companies.
US cloud software company selling industry-specific applications for life sciences (pharma/biotech) companies.
Sells annual subscriptions priced by user or module to drugmakers, who tend to stay for many years because the software holds validated regulatory records. Its newer Vault CRM is replacing the original CRM that ran on Salesforce's platform, so Veeva is moving to its own technology.
Moat: wide (switching costs, regulatory licence, installed base). Deep integration into regulated pharma workflows and validation requirements make switching costly and risky.
Headquarters: Pleasanton, California, US · Founded: 2007 · Employees: 7,928
Size Veeva Systems (VEEV) is a United States Health Care company (Packaged Software) with a market value of $44.9B, the 275th largest of 3,085 United States companies the cockpit tracks. Shares closed at $277.20 on 18 Nov 2026.
Performance Over six months the shares gained 68.0%, against +27.0% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 16.5% over the last twelve months (peer median +9.0%); the operating margin is 29.9% (peer median 18.4%).
Valuation It trades at 28.7× forward earnings against a peer median of 19.2× (6th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Short interest Short interest is 2.4% of the free float (30 Oct 2026).
Next results Next results expected around 3 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $3.46B | $3.20B | $2.75B | $2.36B | $2.16B |
| Revenue growth | — | +16% | +16% | +10% | — |
| Gross profit | $2.59B | $2.40B | $2.03B | $1.67B | $1.53B |
| EBITDA | $1.09B | $997M | $747M | $466M | $497M |
| Net income | $1.01B | $909M | $714M | $526M | $488M |
| Free cash flow | $1.64B | $1.39B | $1.07B | $885M | $767M |
| Capital expenditure | $26.7M | $29.1M | $20.5M | $26.2M | $13.5M |
| Total debt | $152M | $95.9M | $75.8M | $55.8M | $61.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Veeva Systems VEEV | $44.9B | +68% | +16% | 30% | 28.7× | 23.1% |
| Salesforce CRM | $157B | +6% | +11% | 22% | 13.0× | 12.0% |
| Iqvia IQV | $42.5B | +50% | +9% | 14% | 18.7× | 16.8% |
| Oracle ORCL | $344B | -39% | +22% | 34% | 13.3× | n/a |
Peer set: Sector in the same market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VEEV | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.0% | +4.3% | 3rd lowest of 21 |
| 6-month return | +68.0% | +27.0% | highest of 21 |
| Distance from 52-week high | -15.0% | -9.3% | 7th lowest of 21 |
| Revenue growth (TTM) | +16.5% | +9.0% | 5th highest of 20 |
| Operating margin | 29.9% | 18.4% | 5th highest of 21 |
| Forward P/E | 28.7× | 19.2× | 6th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 23.1% | 10.6% | 4th most demanding of 19 |
| Growth delivered (Del g) | +16.9% | +7.0% | 2nd highest of 19 |
| Hurdle (Req g minus delivered) | +6.2 pp | +7.3 pp | 10th least demanding of 19 |
| EV / EBITDA | 34.7× | 19.7× | 3rd most expensive of 17 |
| Net debt / EBITDA | -6.5× | 2.0× | least indebted of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Veeva Systems VEEV | United States | $44.9B | +68% | +16% | 30% | 28.7× | 23.1% | +16.9% |
| Waters WAT | United States | $45.8B | +37% | +81% | 10% | 29.1× | 48.1% | +6.0% |
| Humana HUM | United States | $46.3B | +27% | +22% | 2% | 22.1× | 5.5% | +10.9% |
| Iqvia IQV | United States | $42.5B | +50% | +9% | 14% | 18.7× | 16.8% | +7.5% |
| Natera NTRA | United States | $42.0B | +41% | +37% | -9% | n/a | n/a | n/a |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | United States | $49.3B | +23% | -4% | 19% | 15.0× | 10.5% | +1.0% |
| Agilent Technologies A | United States | $50.0B | +56% | +9% | 24% | 27.0× | 23.3% | +5.4% |
| Royalty Pharma RPRX | United States | $39.4B | +29% | +11% | 66% | 11.5× | 10.8% | +2.3% |
| Medline MDLN | United States | $51.5B | +8% | +12% | 6% | 25.6× | 15.9% | +9.9% |
| GE HealthCare GEHC | United States | $37.8B | +30% | +7% | 14% | 15.6× | 5.0% | +3.7% |
| Biogen BIIB | United States | $37.2B | +34% | +2% | 17% | 17.1× | 10.1% | -5.1% |
| Idexx Laboratories IDXX | United States | $55.0B | +26% | +12% | 32% | 42.9× | 29.0% | +9.7% |
| Zoetis ZTS | United States | $34.8B | +7% | +1% | 37% | 13.8× | -2.9% | +7.2% |
| Revolution Medicines RVMD | United States | $34.6B | +6% | n/a | -853% | n/a | n/a | n/a |
| Mettler Toledo MTD | United States | $34.6B | +60% | +7% | 29% | 33.7× | 20.1% | +5.5% |
| Becton Dickinson BDX | United States | $58.9B | +48% | -7% | 16% | 16.3× | -1.6% | +0.3% |
| ResMed RMD | United States | $34.1B | +16% | +9% | 34% | 19.7× | 5.7% | +12.1% |
| argenx SE Sponsored ADR ARGX | United States | $59.1B | +17% | +71% | 29% | 29.0× | 11.7% | +151.4% |
| Centene CNC | United States | $33.4B | +16% | +10% | 1% | 12.8× | 1.0% | +11.9% |
| Edwards Lifesciences EW | United States | $60.5B | +27% | +13% | 29% | 32.3× | 17.1% | +6.7% |
| Boston Scientific BSX | United States | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% | +15.2% |